St. Jude, Mustang gene therapy produces functional immunity in SCID-X1 patients

St. Jude and Mustang reported late Wednesday that their gene therapy led to fully functioning immune systems in newly diagnosed infants with X-linked severe combined immunodeficiency (SCID-X1) who were treated in the Phase I/II LVXSCID-ND trial. The

Read the full 377 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE